Loco-regional administration of nanomedicines for the treatment of lung cancer

Drug Delivery

Volumn 23, Issue 8, 2016, Pages 2881-2896

  Garrastazu Pereira, Gabriela ^a   Lawson, Amanda Jane ^a   Buttini, Francesca ^b   Sonvico, Fabio ^b  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Chemotherapy; inhalation; local drug delivery; lung cancer; nanomedicine

Indexed keywords

ANTINEOPLASTIC AGENT; MAGNETIC NANOPARTICLE; NANOCARRIER; DELAYED RELEASE FORMULATION; NANOPARTICLE;

AEROSOL; CANCER CHEMOTHERAPY; DRUG FORMULATION; DRY POWDER INHALER; HUMAN; LIQUID; LUNG CANCER; NANOMEDICINE; NEBULIZER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGIONAL PERFUSION; REVIEW; SYSTEMATIC REVIEW (TOPIC); ANIMAL; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; LUNG NEOPLASMS; PROCEDURES; THERAPEUTIC USE;

ANIMALS; ANTINEOPLASTIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; NANOMEDICINE; NANOPARTICLES;

EID: 84947790514     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2015.1114047     Document Type: Review

References (100)

1. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. (2013). Liposome:classification, preparation, and applications. Nanoscale Res Lett 8:102–10
2. Al-Hallak KM, Azarmi S, Anwar-Mohamed A, et al. (2010). Secondary cytotoxicity mediated by alveolar macrophages:a contribution to the total efficacy of nanoparticles in lung cancer therapy? Eur J Pharm Biopharm 76:112–19
3. Anderson PM, Hasz D, Dickrell L, Sencer S. (1992). Interleukin-2 in liposomes:increased venous potency and less pulmonary toxicity in the rat. Drug Dev Res 27:15–31
4. Araya T, Kasagara K, Nishikawa S, et al. (2013). Antitumor effects of inductive hyperthermia using magnetic ferucarbotran. OncoTargets Ther 6:237–42
5. Australian Bureau of Statistics (ABS). (2006). Cancer in Australia:a snapshot, 2004-05. Available at:http://www.abs.gov.au/ausstats/abs@.nsf/mf/4822.0.55.001 [last accessed 31 Aug 2015]
6. Australian Bureau of Statistics (ABS). (2015). Causes of death, Australia, 2013. Available at:http://www.abs.gov.au/AUSSTATS/abs@.nsf/mf/3303.0/ [last accessed 31 Aug 2015]
7. Azarmi S, Tao X, Chen H, et al. (2006). Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm 319:155–61
8. Badrzadeh F, Rahmati-Yamchi M, Badrzadeh K, et al. (2015). Drug delivery and nanodetection in lung cancer. Artif Cells Nanomed Biotechnol. [Epub ahead of print]. doi:10.3109/21691401.2014.975237
9. Baratelli F, Takedatsu H, Hazra S, et al. (2008). Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in Non-Small Cell Lung Cancer. J Transl Med 6:38
10. Blanco E, Hsiao A, Mann AP, et al. (2011). Nanomedicine in cancer therapy:innovative trends and prospects. Cancer Sci 102:1247–52
11. Byron PR. (2004). Drug delivery devices:issues in drug development. Proc Am Thorac Soc 1:321–8
12. Carvalho TC, Carvalho SR, McConville JT. (2011). Formulations for pulmonary administration of anticancer agents to treat lung malignancies. J Aerosol Med Pulm Drug Deliv 24:61–80
13. Celikoglu F, Celikoglu SI, York AM, Goldberg EP. (2006a). Intratumoral administration of cisplatin through a bronchoscope followed by irradiation for treatment of inoperable non-small cell obstructive lung cancer. Lung Cancer 51:225–36
14. Celikoglu F, Celikoglu SI, Goldberg EP. (2008). Bronchoscopic intratumoral chemotherapy of lung cancer. Lung Cancer 61:1–12
15. Celikoglu F, Celikoglu SI, Goldberg EP. (2010). Intratumoral chemotherapy of lung cancer for diagnosis and draining of lymph node metastases. J Pharm Pharmacol 62:287–93
16. Celikoglu SI, Celikoglu F, Goldberg EP. (2006b). Endobronchial intratumoral chemotherapy (EITC) followed by surgery in early non-small cell lung cancer with polyploid growth causing erroneous impression of advanced disease. Lung Cancer 54:339–46
17. Chang HI, Yeh MK. (2012). Clinical development of liposome-based drugs:formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 7:49–60
18. Chou AJ, Gupta R, Bell MD, et al. (2013). Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. Pediatr Blood Cancer 60:580–6
19. Colombo P, Sonvico F, Buttini F. (2012). Nanostructures overcoming the pulmonary barrier:drug delivery strategies. In Alonso MJ, Csaba NS, eds. Nanostructured biomaterials for overcoming biological barriers. London:Royal Society of Chemistry, 273–300
20. Dailey LA, Kleemann E, Wittmar M, et al. (2003). Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA. Pharm Res 20:2011–20
21. Dailey LA, Jekel N, Fink L, et al. (2006). Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol 215:100–8
22. Darwiche K, Zarogoulidis P, Karamanos NK, et al. (2013). Efficacy versus safety concerns for aerosol chemotherapy in non-small-cell lung cancer:a future dilemma for micro-oncology. Future Oncol 9:505–25
23. De Souza R, Zahedi P, Allen CJ, Piquette-Miller M. (2010). Polymeric drug delivery systems for localized cancer chemotherapy. Drug Deliv 17:365–75
24. Dolovich MB, Ahrens RC, Hess DR, et al. (2005). Device selection and outcomes of aerosol therapy:evidence-based guidelines. Chest 127:335–71
25. Dufort S, Bianchi A, Henry M, et al. (2015). Nebulized gadolinium-based nanoparticles:a theranostic approach for lung tumor imaging and radiosensitization. Small 11:215–21
26. El-Gendy N, Berkland C. (2009). Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res 26:1752–63
27. Feng R, Zhang Z, Li Z, Huang G. (2014). Preparation and in vitro evaluation of etoposide-loaded PLGA microspheres for pulmonary drug delivery. Drug Deliv 21(3):185–92
28. Fulzele SV, Shaik MS, Chatterjee A, Singh M. (2006). Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549. J Pharm Pharmacol 58:327–36
29. Garbuzenko OB, Mainelis G, Taratula O, Minko T. (2014a). Inhalation treatment of lung cancer:the influence of composition, size and shape of nanocarriers on their lung accumulation and retention. Cancer Biol Med 11:44–55
30. Garbuzenko OB, Winkler J, Tomassone MS, Minko T. (2014b). Biodegradable Janus nanoparticles for local pulmonary delivery of hydrophilic and hydrophobic molecules to the lungs. Langmuir 30:12941–9
31. Geller DE. (2002). New liquid aerosol generation devices:systems that force pressurized liquids through nozzles. Respir Care 47:1392–404
32. Gill KK, Nazzal S, Kaddoumi A. (2011). Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform:formulation characterisation, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur J Pharm Biopharm 79:276–84
33. Hanahan D, Weinberg RA. (2011). Hallmarks of cancer:the next Generation. Cell 144:646–74
34. Hart MG, Grant R, Garside R, et al. (2011). Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev 2011:CD007294
35. Haynes A, Shaik MS, Chatterjee A, Singh M. (2003). Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line. Pharm Res 20:1485–95
36. Hernández-Trejo N, Kayser O, Steckel H, Müller RH. (2005). Characterization of nebulized buparvaquone nanosuspensions–effect of nebulization technology. J Drug Target 13:499–507
37. Hoet PH, Brüske-Hohlfeld I, Salata OV. (2004). Nanoparticles–known and unknown health risks. J Nanobiotechnol 2:12
38. Holback H, Yeo Y. (2011). Intratumoral drug delivery with nanoparticulate carriers. Pharm Res 28:1819–30
39. Ibald-Mulli A, Wichman HE, Kreyling W, Peters A. (2002). Epidemiological evidence on health effects of ultrafine particles. J Aerosol Med 15:189–201
40. 4 nanoparticles and doxorubicin into biodegradable PLGA nano-carriers for intratumoral delivery. Int J Nanomedicine 7:1697–708
41. Jinturkar KA, Anish C, Kumar MK, et al. (2012). Liposomal formulations of etoposide and docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines. Biomaterials 33:2492–507
42. Jones MC, Jones SA, Riffo-Vasquez Y, et al. (2014). Quantitative assessment of nanoparticle surface hydrophobicity and its influence on pulmonary biocompatibility. J Control Release 183:94–104
43. Joshi N, Shanmugam T, Kaviratna A, Banerjee R. (2011). Proapoptotic lipid nanovesicles:synergism with paclitaxel in human lung adenocarcinoma A549 cells. J Control Release 156:413–20
44. Joshi N, Shirsath N, Singh A, et al. (2014). Endogenous lung surfactant inspired pH responsive nanovesicle aerosols:pulmonary compatible and site-specific drug delivery in lung metastases. Sci Rep 4:7085
45. Jyoti K, Kaur K, Pandey RS, et al. (2015). Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent:In vitro and in vivo studies. J Colloid Interface Sci 445:219–30
46. Kang YM, Kim GH, Kim JI, et al. (2011). In vivo efficacy of an intratumorally injected in situ forming doxorubicin/poly(ethylene glycol)-β-caprolactone diblock copolymer. Biomaterials 32:4556–64
47. Kar UK, Srivastava MK, Andersson A, et al. (2011). Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS One 6:e18758
48. Kaur P, Garg T, Rath G, et al. (2015). Surfactant-based drug delivery systems for treating drug-resistant lung cancer. Drug Deliv 21:1–2. doi:10.3109/10717544.2014.935530
49. Khanna C, Anderson PM, Hasz DE, et al. (1997). Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 79:1409–21
50. Kleinstreuer C, Zhang Z, Donohue JF. (2008). Targeted drug-aerosol delivery in the human respiratory system. Annu Rev Biomed Eng 10:195–220
51. Knight V, Koshkina NV, Waldrep JC, et al. (1999). Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol 44:177–86
52. Koshkina NV, Kleinerman ES, Waidrep C, et al. (2000). 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res 6:2876–80
53. 2 enriched air:pharmacokinetic studies. Cancer Chemother Pharmacol 47:451–6
54. Koshkina NV, Waldrep JC, Knight V. (2003). Camptothecins and lung cancer:improved delivery systems by aerosol. Curr Cancer Drug Targets 3:251–64
55. Labiris NR, Dolovich MB. (2003). Pulmonary drug delivery. Part II:the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. J Clin Pharmacol 56:600–12
56. Lebhardt T, Roesler S, Uusitalo HP, Kissel T. (2011). Surfactant-free redispersible nanoparticles in fast-dissolving composite microcarriers for dry-powder inhalation. Eur J Pharm Biopharm 78:90–6
57. Liu R, Wolinsky JB, Walpole J, et al. (2010). Prevention of local tumour recurrence following surgery using low dose chemotherapeutic polymer films. Ann Surg Oncol 17:1203–13
58. Long JT, Cheang TY, Zhuo SY, et al. (2014). Anticancer drug-loaded multifunctional nanoparticles to enhance the chemotherapeutic efficacy in lung cancer metastasis. J Nanobiotechnol 12:37
59. Lowe SW, Bodis S, McClatchey A, et al. (1994). p53 status and the efficacy of cancer therapy in vivo. Science 266:807–10
60. Lukyanov AN, Torchilin VP. (2004). Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev 56:1273–89
61. Mansour HM, Rhee YS, Wu X. (2009). Nanomedicine in pulmonary delivery. Int J Nanomedicine 4:299–319
62. Meenach SA, Anderson KW, Zach Hilt J, et al. (2013). Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Eur J Pharm Sci 49:699–711
63. Misra A, Jinturkar K, Patel D, et al. (2009). Recent advances in liposomal dry powder formulations:preparation and evaluation. Expert Opin Drug Deliv 6:71–89
64. Muralidharan P, Malapit M, Mallory E, et al. (2015). Inhalable nanoparticulate powders for respiratory delivery. Nanomedicine 11:1189–99
65. Oberdörster G, Oberdörster E, Oberdörster J. (2005). Nanotoxicology:an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 113:823–39
66. Parker DM. (2001). Global cancer statistics in the year 2000. Lancet Oncol 2:533–43
67. Patlolla RR, Chougule M, Patel AR, et al. (2010). Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release 144:233–41
68. Patton JS, Byron PR. (2007). Inhaling medicines:delivering drugs to the body through the lungs. Nat Rev Drug Discov 6:67–74
69. Rao RD, Markovic SN, Anderson PM. (2003). Aerosol therapy for malignancy involving the lungs. Curr Cancer Drug Targets 3:238–50
70. Roa WH, Azarmi S, Al-Hallak MH, et al. (2011). Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J Control Release 150:49–55
71. Rotoli BM, Gatti R, Movia D, et al. (2015). Identifying contact-mediated, localized toxic effects of MWCNT aggregates on epithelial monolayers:a single-cell monitoring toxicity assay. Nanotoxicology 9:230–41
72. Sadhukha T, Wiedmann TS, Panyam J. (2013). Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy. Biomaterials 34:5163–71
73. Sharma S, Stolina M, Luo J, et al. (2000). Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 164:4558–63
74. Singh J, Garg T, Rath G, Goyal AK. (2015). Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis–a critical review. Drug Deliv. [Epub ahead of print]. doi:10.3109/10717544.2015.1074765
75. Skubitz KM, Anderson PM. (2000). Inhalational interleukin-2 liposomes for pulmonary metastases:a phase I clinical trial. Anticancer Drugs 11:555–63
76. Sonvico F, Dubernet C, Colombo P, Couvreur P. (2005). Metallic colloid nanotechnology, applications in diagnosis and therapeutics. Curr Pharm Des 11:2095–105
77. Taratula O, Garbuzenko OB, Chen AM, Minko T. (2011). Innovative strategy for treatment of lung cancer:targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target 19:900–14
78. Taratula O, Kuzmov A, Shah M, et al. (2013). Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release 171:349–57
79. Tewes F, Ehrhardt C, Healy AM. (2014). Superparamagnetic iron oxide nanoparticles (SPIONs)-loaded Trojan microparticles for targeted aerosol delivery to the lung. Eur J Pharm Biopharm 86:98–104
80. Thiesen B, Jordan A. (2008). Clinical applications of magnetic nanoparticles for hyperthermia. Int J Hyperthermia 24:467–74
81. Tomoda K, Ohkoshi T, Hirota K, et al. (2009). Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. Colloids Surf B Biointerfaces 71:177–82
82. Torchilin VP. (2005). Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145–60
83. Tseng CL, Su WY, Yen KC, et al. (2009). The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 30:3476–85
84. Verma NK, Crosbie-Staunton K, Satti A, et al. (2013). Magnetic core-shell nanoparticles for drug delivery by nebulisation. J Nanobiotechnol 11:1–12
85. Verschraegen CF, Gilbert BE, Loyer E, et al. (2004). Clinical evaluation of the delivery and safety of aerosolised liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 10:2319–26
86. Videira M, Almeida AJ, Fabra A. (2012). Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect. Nanomedicine 8:1208–15
87. Wang C, Chen T. (2012). Intratumoral injection of Taxol in vivo suppresses A549 tumor showing cytoplasmic vacuolisation. J Cell Biochem 113:1397–406
88. Westphal M, Hilt DC, Bortey E, et al. (2006). A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79–88
89. Willis L, Hayes D, Jr, Mansour HM. (2012). Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung 190:251–62
90. Wittgen BP, Kunst PW, Perkins WR, et al. (2006). Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin. J Aerosol Med 19:385–91
91. Wittgen BP, Kunst PW, van der Born K, et al. (2007). Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res 13:2414–21
92. Wolinsky JB, Colson YL, Grinstaff MW. (2012). Local drug delivery strategies for cancer treatment:gels, nanoparticles, polymeric films, rods, and wafers. J Control Release 159:14–26
93. Yohe ST, Colson YL, Grinstaff MW. (2012a). Superhydrophobic materials for tuneable drug release:using displacement of air to control delivery rates. JACS 134:2016–19
94. Yohe ST, Herrera VL, Colson YL, Grinstaff MW. (2012b). 3D superhydrophobic electrospun meshes as reinforcement materials for sustained local drug delivery against colorectal cancer cells. J Control Release 162:92–101
95. Yoo GH, Subramanian G, Ezzat WH, et al. (2010). Intratumoral delivery of docetaxel enhances antitumor activity of Ad-p53 in murine head and neck cancer xenograft model. Am J Otolaryngol 31:78–83
96. Yu Y, Kong L, Li L, et al. (2015). Antitumor activity of doxorubicin-loaded carbon nanotubes incorporated poly(lactic-co-glycolic acid) electrospun composite nanofibers. Nanoscale Res Lett 10:3434
97. Zarogoulidis P, Chatzaki E, Porpodis K, et al. (2012a). Inhaled chemotherapy in lung cancer:future concept of nanomedicine. Int J Nanomedicine 7:1551–72
98. Zarogoulidis P, Gialeli C, Karamanos NK. (2012b). Inhaled chemotherapy in lung cancer:safety concerns of nanocomplexes delivered. Ther Deliv 3:1021–23
99. Zhang Z, Kleinstreuer C, Kim CS. (2008). Airflow and nanoparticle deposition in a 16-generation tracheobronchial airway model. Ann Biomed Eng 36:2095–110
100. Zhang Z, Mei L, Feng SS. (2013). Paclitaxel drug delivery systems. Exp Opin Drug Deliv 10:325–40